Reverse remodeling in diabetic cardiomyopathy: the role of extracellular matrix

Area of Science:

• Cardiology
• Endocrinology
• Biomedical Engineering

Background:

• Diabetic patients face high risks of cardiovascular diseases, including ischemic heart disease and diabetic cardiomyopathy.
• Cardiac fibrosis, driven by extracellular matrix (ECM) remodeling, is a key pathological feature in diabetes, leading to heart failure.
• Dysfunctional ECM at the single-cell level impacts cardiomyocyte metabolism, motility, and proliferation.

Purpose of the Study:

• To review the mechanisms of ECM remodeling in diabetic cardiomyopathy.
• To explore the role of ECM reverse remodeling as a therapeutic target.
• To discuss the antifibrotic effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Main Methods:

• Literature review focusing on ECM remodeling in diabetic cardiomyopathy.
• Analysis of studies on the impact of diabetes on cardiac extracellular matrix.
• Examination of research on SGLT2 inhibitors and their effects on cardiac fibrosis.

Main Results:

• Diabetes-induced ECM alterations promote cardiac fibrosis, stiffness, and cardiomyocyte dysfunction.
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrate potential antifibrotic effects.
• ECM reverse remodeling emerges as a promising therapeutic strategy for diabetic cardiomyopathy.

Conclusions:

• Targeting ECM remodeling and promoting reverse remodeling holds therapeutic potential for diabetic cardiomyopathy.
• SGLT2 inhibitors represent a promising class of drugs for managing cardiac complications in diabetes.
• Further research into ECM modulation is crucial for improving outcomes in diabetic cardiovascular disease.